EAST.V - EastWest Bioscience Inc.
| Previous Close | 0.0350 |
| Open | 0.0350 |
| Bid | 0.0300 x 0 |
| Ask | 0.0350 x 0 |
| Day's Range | 0.0350 - 0.0350 |
| 52 Week Range | 0.0100 - 0.0850 |
| Volume | 44,001 |
| Avg. Volume | 1,081,535 |
| Market Cap | 3.241M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0250 |
| Earnings Date | Jul. 02, 2020 - Jul. 06, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
EastWest Bioscience Reports Third Quarter Fiscal 2020 Financial Results
The Company reported total revenue of $231,248, as compared to $699,991 in the prior year, a decrease of $468,743. Began manufacturing Hand Sanitizer in Ontario and at its Penticton facility in June. In Canada, Eastwest is experiencing a strong order book of 2 months out for its Nutraceutical Manufacturing and has added a second shift to accommodate the demand.
- ACCESSWIRE
EastWest Bioscience Announces Closing of Private Placement and Settlement of Debts for Shares
PENTICTON, BC / ACCESSWIRE / June 25, 2020 / EastWest Bioscience (the "Company" or "EastWest") (EAST.V) is pleased to announce that further to the Company's press release dated June 18, 2020, the Company has closed a private placement financing with the issuance of 1,992,727 common shares at a price of $0.05 per common share for aggregate proceeds of $99,636.37. The private placement was subscribed by one investee Summit Bancorp. The proceeds from the private placement will be used for general corporate purposes.
- ACCESSWIRE
EastWest Bioscience Announces Private Placement
VANCOUVER, BC / ACCESSWIRE / June 18, 2020 / EastWest Bioscience (the "Company" or "EastWest") (EAST.V) announces that it intends to conduct a private placement financing of up to 2,000,000 common shares at a price of $0.05 per common share for aggregate proceeds of up to $100,000. The proceeds from the private placement will be used for general corporate purposes. The common shares issued pursuant to this private placement will be subject to TSX Venture Exchange approval and a statutory four-month hold period in accordance with applicable securities laws.
- ACCESSWIRE
EastWest Bioscience Announces Settlement of Debts for Shares
VANCOUVER, BC / ACCESSWIRE / June 15, 2020 / EastWest Bioscience (the "Company" or "EastWest") (EAST.V) announces the issuance of approximately 6,007,270 common shares at a price of CDN $0.05 per common share to certain arms length and non-arms length individuals and service providers for settlement of a significant portion owing by the Company in respect of various services rendered, including but not limited to consulting, accounting and legal, and for settlement of loans and/of advances provided to the Company. All of the common shares issued pursuant to these arrangements are subject to TSX Venture Exchange approval and a statutory four-month hold period in accordance with applicable securities laws. EastWest Bioscience is a vertically integrated wellness company with the infrastructure to become a global giant in the Hemp & CBD consumer health market.
- ACCESSWIRE
EastWest Bioscience Receives Additional Health Canada Approval for Hand Sanitizer
PENTICTON, BC / ACCESSWIRE / June 2, 2020 / EastWest Bioscience's ("EastWest") (EAST.V) manufacturing subsidiary, Orchard Vale Naturals ("Orchard Vale" or the "Company"), has received additional Health Canada approval for hand sanitizer. This will secure our supply of material required to meet the market demand. When EastWest entered the hand sanitizer space, it was apparent from the beginning that the demand for these products would not be an issue.
- ACCESSWIRE
EastWest Bioscience 80% Ethyl Alcohol Hand Sanitizer Receives FDA Approval
PENTICTON, BC / ACCESSWIRE / May 28, 2020 / EastWest Bioscience's ("EastWest") (EAST.V) manufacturing subsidiary, Orchard Vale Naturals ("Orchard Vale" or the "Company"), has received U.S. Food and Drug Administration ("FDA") approval for its 80% ethyl alcohol hand sanitizer liquid spray. This will allow Orchard Vale to distribute its hand sanitizer to the American market, adding revenue streams to its US operation. The 80% Ethyl Alcohol provides the Company significant latitude in its customer base.
- ACCESSWIRE
EastWest BioScience Supplement Manufacturing Division Expands Production to Meet Increased Demand During Pandemic
PENTICTON, BC / ACCESSWIRE / May 20, 2020 / EastWest Bioscience's ("EastWest") (EAST.V) manufacturing subsidiary, Orchard Vale Naturals ("Orchard Vale"), has seen a substantial increase in its manufacturing orders due to surging demand for health and wellness products during the COVID-19 pandemic. Currently, Orchard Vale's production calendar is at an 8 week backlog. Orchard Vale is also preparing for the manufacturing of hand sanitizers that initially would be distributed through its sister company, Sangster's Health Centres, across its Canada wide locations and its existing independent distribution network.
- ACCESSWIRE
Hand Sanitizer Approval from Health Canada
PENTICTON, BC / ACCESSWIRE / May 19, 2020 / EastWest Bioscience's (the "Company" or "EastWest") (EAST.V) subsidiary, Orchard Vale Naturals ("Orchard Vale"), has received Health Canada approval for hand sanitizer liquid spray. Manufacturing and shipping of finished products are scheduled to be completed by the end of May at our Penticton, BC facility. Initially, Orchard Vale intends to sell its hand sanitizer spray through the Sangsters retail locations and through its various distribution networks in Canada.
- Newsfile
Early Warning Report in Accordance with National Instrument 62-103
Penticton, British Columbia--(Newsfile Corp. - April 29, 2020) - Mr. Rodney Gelineau issues this press release pursuant to Part 3 - Early Warning Requirements of National Instrument 62-103 with respect to EastWest Bioscience Inc. ("EastWest").Mr. Rodney Gelineau, the President and CEO of EastWest has directly acquired 100,000 common shares by a series of purchases through the facilities of the TSX Venture Exchange at $.015 per share on April 24, 2020 (the "Shares"). Prior ...
- GlobeNewswire
EASTWEST REPORTS IMPROVED FINANCIAL RESULTS FOR SECOND QUARTER OF FISCAL 2020
EastWest Bioscience Inc. (the “Company” or “EastWest”) (EAST.V) has released its second quarter results for the three months ending January 31, 2020. The Company reported revenues for the three months ended January 31, 2020 (“Q2 2020”) were $370,017 compared to $528,199 in the three months ended January 31, 2019 (“Q2 2019”). While revenues declined, the Company realized higher margins, lower expenditures, and a lower net and comprehensive loss in Q2 2020 compared to Q2 2019.
- ACCESSWIRE
EastWest Files First Quarter 2020 Interim Financial Statements and Provides Update Regarding Management Cease-Trade Order
VANCOUVER, BC / ACCESSWIRE / February 11, 2020 / EastWest Bioscience Inc. ("EastWest" or the "Corporation") announces that it filed its interim financial statements for the three months ended October 31, 2019, related management discussion and analysis and applicable officer certificates (collectively, the "Quarter One Filings"). The Corporation is now current on its continuous disclosure requirements. On November 29, 2019, the Corporation announced the delay in the filing of its audited annual financial statements for the year ended July 31, 2019 and related management discussion and analysis and certifications (collectively, the "Annual Filings") by the filing deadline of November 28, 2019.
- ACCESSWIRE
Construction Completed on EastWest's Kentucky, USA CBD Processing and Bottling Line
LEBANON, KY / ACCRESSWIRE / February 6, 2020 / EastWest Bioscience (the "Company" or "EastWest") (EAST.V) announces that, further to its News Release on November 27th, the Company is pleased to announce that construction is completed on its CBD processing and bottling line in Lebanon, Kentucky. The CBD manufacturing line is part of its 50/50 joint venture with Azema Sciences through its US division, EastWest Science USA ("EastWest USA"). The Joint Venture provides EastWest USA with continuous supply of premium CBD, as it is developing value added CBD consumer goods for the US market for the pet, skin care, functional food and supplement categories.
- Simply Wall St.
Have Insiders Been Buying EastWest Bioscience Inc. (CVE:EAST) Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- ACCESSWIRE
EastWest Files Audited 2019 Annual Financial Statements and Provides Fifth Status Report Regarding Management Cease-Trade Order
The Corporation has not yet filed its interim financial statements for the three month period ended October 31, 2019 (the "Quarter One Financial Statements"), the accompanying management's discussion and analysis and the related CEO and CFO certifications (the "Quarter One Filings"), which were due on December 30, 2019. The Company provides this default status report in accordance with National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203"). In its initial default announcement of November 29, 2019 (the "Default Notice"), the Corporation announced the delay in the filing of its Annual Filings by the filing deadline of November 28, 2019.
- ACCESSWIRE
EastWest Issues Fourth Bi-Weekly Status Report Regarding Management Cease-Trade Order
In its initial default announcement of November 29, 2019 (the "Default Notice"), the Corporation announced the delay in the filing of its audited annual financial statements for the year ended July 31, 2019 (the "2019 Annual Financial Statements") and related management discussion and analysis and certifications (collectively, the "Annual Filings") by the filing deadline of November 28, 2019. The Company subsequently provided bi-weekly default status reports on December 12, 2019, December 27, 2019 and January 10, 2020.
- ACCESSWIRE
EastWest Bioscience to Close Debt Settlement Arrangement
The Corporation will settle outstanding indebtedness to an arm's length creditor in the amount of $13,750 in exchange for 275,000 common shares of the Corporation at a price of $0.05 per common share. EastWest Bioscience is a vertically integrated wellness corporation with the infrastructure to become a global giant in the Hemp & CBD consumer health market. Since it was founded in 2016, EastWest continues to grow as a high-quality producer, manufacturer and distributor of multiple lines of premium health and hemp products.
- ACCESSWIRE
EastWest Issues Third Bi-weekly Status Report Regarding Management Cease-Trade Order
In its initial default announcement of November 29, 2019 (the "Default Notice"), the Corporation announced the delay in the filing of its audited annual financial statements for the year ended July 31, 2019 (the "2019 Annual Financial Statements") and related management discussion and analysis and certifications (collectively, the "Annual Filings") by the filing deadline of November 28, 2019. The Company subsequently provided bi-weekly default status reports on December 12, 2019 and December 27, 2019.
- ACCESSWIRE
EastWest Issues Second Bi-Weekly Status Report Regarding Management Cease-Trade Order
VANCOUVER, BC / ACCESSWIRE / December 27, 2019 / EastWest Bioscience Inc. ("EastWest" or the "Corporation") provides this bi-weekly default status report in accordance with National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203"). In its initial default announcement of November 29, 2019 (the "Default Notice"), the Corporation announced the delay in the filing of its audited annual financial statements for the year ended July 31, 2019 (the "2019 Annual Financial Statements") and related management discussion and analysis and certifications (collectively, the "Annual Filings") by the filing deadline of November 28, 2019. The Company subsequently provided a bi-weekly default status report on December 12, 2019.
- ACCESSWIRE
EastWest Bioscience to Acquire Shares of 1123573 BC Ltd. and Orchard Valley Naturals Ltd.
VANCOUVER, BC / ACCESSWIRE / December 18, 2019 / EastWest Bioscience (the "Company" or "EastWest") (EAST.V) announces that it has entered a share purchase agreement (the "Agreement") with Darryl Sangster, Aquila Health Corp. and Sangster's Real Estate Corp. (collectively, the "Sangster Parties") for the purchase of shares of 1123573 BC Ltd. ("573") and Orchard Valley Naturals Inc. ("Valley"). Completion of the Agreement is subject to the approval of the TSX Venture Exchange. EastWest currently holds 50% of the shares of 573 and Valley.
- ACCESSWIRE
EastWest Issues Bi-Weekly Status Report Regarding Management Cease-Trade Order
VANCOUVER, BC / ACCESSWIRE / December 12, 2019 / Eastwest Bioscience Inc. ("Eastwest" or the "Corporation") provides this bi-weekly default status report in accordance with National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203"). In its initial default announcement of November 29, 2019 (the "Default Notice"), the Corporation announced the delay in the filing of its audited annual financial statements for the year ended July 31, 2019 (the "2019 Annual Financial Statements") and related management discussion and analysis and certifications (collectively, the "Annual Filings") by the filing deadline of November 28, 2019. As previously announced, the Corporation applied for and was granted management cease trade orders in respect of the delayed Annual Filings (the "MCTO") by the British Columbia Securities Commission and the Financial and Consumer Affairs Division of Saskatchewan which prohibit the chief financial officer and the chief executive officer from trading in the Corporation's securities for so long as there are filings that are outstanding under applicable securities laws.
- ACCESSWIRE
Default Announcement
VANCOUVER, BC / ACCESSWIRE / November 29, 2019 / Eastwest Bioscience Inc. ("Eastwest" or the "Corporation") provides this default announcement indicating Eastwest's anticipated failure to file its annual financial statements for the year ended July 31, 2019 and related management discussion and analysis and certifications (collectively, the "Financial Statements") before the prescribed filing deadlines. The Corporation acquired Sangster's Health Centres ("Sangster's") with three subsidiaries on November 30, 2018.
- ACCESSWIRE
EastWest Bioscience Continues Expansion into the US market with the Construction on its CBD Processing and Bottling Line Nearing Completion
LEBANON, KY / ACCESSWIRE / November 27, 2019 / EastWest Bioscience (the "Company" or "EastWest") (EAST.V) announces that, further to its News Release on June 20th, the Company is pleased to announce that construction is nearing completion on its CBD processing and bottling line in Lebanon, Kentucky. The CBD manufacturing line is part of its 50/50 joint venture with Azema Sciences through its US division, EastWest Science USA ("EastWest USA") and is targeted to be completed by December 15, 2019. The Joint Venture provides EastWest USA with continuous supply of premium CBD, as it is developing value added CBD consumer goods for the US market for the pet, skin care, functional food and supplement categories.
- ACCESSWIRE
InnerScope Hearing Technologies Inc. (OTCQB: INND) Establishes a Distribution, Warehousing, and Manufacturing Agreement in Canada and the United States with EASTWEST BIOSCIENCE INC. (TSX.V: EAST)
EASTWEST BIOSCIENCE INC. and InnerScope Hearing Technologies Inc. have entered into an Agreement for both companies to establish distribution and marketing rights to include warehousing and distribution ...
- GlobeNewswire
InnerScope Hearing Technologies (OTCQB: INND) Establishes a Distribution, Warehousing, and Manufacturing Agreement in Canada and the United States with EASTWEST BIOSCIENCE (TSX.V: EAST)
ROSEVILLE, Calif. and VANCOUVER, B.C., Nov. 06, 2019 -- via OTC PR WIRE -- InnerScope Hearing Technologies Inc. (OTCQB: INND) ("InnerScope") a manufacturer and.
